These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 25698450)

  • 1. Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
    Des Guetz G; Landre T; Westeel V; Milleron B; Vaylet F; Urban T; Barlesi F; Souquet PJ; Debieuvre D; Braun D; Fraboulet G; Monnet I; Uzzan B; Molinier O; Morin F; Moro-Sibilot D; Morère JF
    J Geriatr Oncol; 2015 May; 6(3):233-40. PubMed ID: 25698450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
    Morère JF; Bréchot JM; Westeel V; Gounant V; Lebeau B; Vaylet F; Barlési F; Urban T; Souquet PJ; Debieuvre D; Baudrin L; Zalcman G; Morin F; Milleron B; Moro-Sibilot D
    Lung Cancer; 2010 Dec; 70(3):301-7. PubMed ID: 20400201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study.
    Karampeazis A; Vamvakas L; Kotsakis A; Christophyllakis C; Kentepozidis N; Chandrinos V; Agelidou A; Polyzos A; Tsiafaki X; Hatzidaki D; Georgoulias V
    J Geriatr Oncol; 2017 Jan; 8(1):23-30. PubMed ID: 27264267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
    Duruisseaux M; Baudrin L; Quoix E; Wislez M; Moro-Sibilot D; Coëtmeur D; Monnet I; Mourlanette P; Morère JF; Soria JC; Westeel V; Morin F; Cadranel J
    J Thorac Oncol; 2012 Sep; 7(9):1423-31. PubMed ID: 22767177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
    Maemondo M; Inoue A; Sugawara S; Harada T; Minegishi Y; Usui K; Miwa K; Morikawa N; Kambe M; Ube K; Watanabe K; Ishimoto O; Sakakibara T; Gemma A; Nukiwa T
    Oncologist; 2014 Apr; 19(4):352-3. PubMed ID: 24682465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
    Stinchcombe TE; Roder J; Peterman AH; Grigorieva J; Lee CB; Moore DT; Socinski MA
    J Thorac Oncol; 2013 Apr; 8(4):443-51. PubMed ID: 23370367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
    Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
    Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.
    Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B
    Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Erland JB; Barton JH; Thompson DS; Stagg MP; Bradof JE; Twele TW; Greco EA;
    Clin Lung Cancer; 2003 Jul; 5(1):33-8. PubMed ID: 14596701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
    Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
    Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
    Liu S; Wang D; Chen B; Wang Y; Zhao W; Wu J
    Lung Cancer; 2011 Aug; 73(2):203-10. PubMed ID: 21211862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
    Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
    J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
    Sun Y; Wu YL; Li LY; Liao ML; Jiang GL; Kim ES; Douillard JY; Milenkova T
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):377-80. PubMed ID: 21875470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
    Zhao YL; Han S; Pu R; Shi LW
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e86-91. PubMed ID: 25818741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.